Khan Habib, Chaubey Sanjay, Desai Jatin
Department of Cardiothoracic Surgery, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.
J Card Surg. 2011 May;26(3):264-6. doi: 10.1111/j.1540-8191.2011.01208.x. Epub 2011 Feb 22.
Bioglue which constitutes albumin cross linked with glutaraldehyde (ACLG) produced by Cryolife, Inc, Kennesaw, GA was introduced as a better alternative to GRF glue with less tissue necrosis. We report a case of a 69-year-old male who developed stenosis of his saphenous vein and internal thoracic artery bypass grafts, requiring re-do coronary artery bypass grafting. Both fibrotic narrowing were in close proximity to the site of Bioglue application and appears to be a reaction to the glue. The advent of ACLG has facilitated surgery; however, this case highlights a potential side effect, emphasizing the judicious use of this hemostatic agent in patients.
由佐治亚州肯尼索市的Cryolife公司生产的BioGlue，即与戊二醛交联的白蛋白（ACLG），作为一种比GRF胶水更好的替代品被引入，其导致的组织坏死较少。我们报告一例69岁男性病例，该患者出现大隐静脉和胸廓内动脉搭桥移植血管狭窄，需要再次进行冠状动脉搭桥移植术。两处纤维化狭窄均紧邻BioGlue应用部位，似乎是对胶水的反应。ACLG的出现促进了手术；然而，该病例突出了一个潜在的副作用，强调在患者中谨慎使用这种止血剂。
